Results 61 to 70 of about 50,723 (266)

Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition). [PDF]

Cancer Innov
This consensus, based on the latest evidence‐based medical data, provides guidance on the standardized application and safety management of PARP inhibitors in breast cancer treatment, aiming to serve as a reference for clinical practice. ABSTRACT Breast cancer represents a major threat to women's health in China.
Ma F, Xu B, China Anti‐Cancer Association Committee on Clinical Research of Anticancer Drugs, National Expert Committee on Monitoring Clinical Application of Antineoplastic Drugs, Breast Cancer Expert Committee of National Cancer Quality Control Center, Expert Committee on Chemotherapy Quality Control of Beijing Cancer Treatment Quality Control and Improvement Center.   +5 more
europepmc   +2 more sources

Tumor‐Intrinsic ARHGEF3 Enhances Antitumor Immunity by Promoting T‐Cell Infiltration and Limiting Myeloid Cell‐Mediated Immunosuppression

Advanced Science, EarlyView.
ARHGEF3 is broadly downregulated across human cancers and correlates with patient prognosis. Tumor‐intrinsic ARHGEF3 activates the RHOA–ROCK–PTEN cascade to inhibit AKT signaling, thereby promoting chemokine‐driven T‐cell infiltration and relieving lipid‐mediated myeloid immunosuppression.
Yue Li, Lan Wang, Zihao Zhang, Chunmei Qian, Ning Li, Wei Huang, Qian Ba, Xiaojian Liu, Mayu Sun   +8 more
wiley   +1 more source

Combining Spatial Multi‐Omics Data to Decipher Spatial Domains and Elucidate Cell Heterogeneity Based on Self‐Supervised Graph Learning

Advanced Science, EarlyView.
A self‐supervised multi‐view graph fusion framework integrates spatial multi‐omics, excelling in domain identification and denoising. It reconstructs spatial pseudo‐expression, jointly analyzes multi‐omics data, infers RNA velocity, predicts spatial omics features from single‐cell multi‐omics, and detects spatially dark genes and transcription factors,
Yuejing Lu, Rui Qiao, Ying Li, Junhong Li, Nuoya Yue, Jing Ge, Jiao Wang, Luonan Chen, Peiluan Li   +8 more
wiley   +1 more source

BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects

Cancer Management and Research, 2020
Winston Wong,1 Alexander G Raufi,1,2 Rachael A Safyan,1 Susan E Bates,1,3 Gulam A Manji1,4 1Division of Hematology and Oncology, Columbia University Medical Center and New York Presbyterian Hospital Herbert Irving Pavilion, New York, NY 10032, USA ...
Wong W, Raufi AG, Safyan RA, Bates SE, Manji GA   +4 more
doaj  

Genetic predisposition for ovarian cancer development [PDF]

Arhiv za farmaciju
Ovarian cancer is a leading malignancy in the female reproductive system and is responsible for more deaths than any other type of cancer affecting this system. Ovarian cancers can be hereditary or sporadic.
Joksić Ivana, Prosenc-Zmrzljak Uršula, Ninić Ana, Ratković Tamara, Munjas Jelena   +4 more
doaj   +1 more source

Treatment of women with BRCA mutation

Climacteric, 2023
The cumulative risk for breast and ovarian cancer is high in BRCA1 or BRCA2 mutation carriers. The lifetime risk of breast cancer by the age of 80 years is respectively up to 72% and 69% in BRCA1 and BRCA2 mutation carriers. The risk of ovarian cancer is higher (44%) in BRCA1 than in BRCA2 (17%) mutation carriers.
openaire   +2 more sources

Lighting up Macrophage Reprogramming Assists Immunosuppressive Niche Modulation in Primary Tumors and Tumor‐Draining Lymph Nodes of Breast Cancer

Advanced Science, EarlyView.
This study develops an intelligent NIR‐II‐responsive nanoplatform to combat immunosuppression in breast cancer. It enables real‐time visualization of macrophage activity via “off‐on” fluorescence while simultaneously reprogramming macrophages through the CSF‐1R and CD47‐SIRPα pathways.
Yingbo Li, Di Chang, Jie Yang, Ying Bai, Min Chen, Daoshuang Li, Zuoyu Xu, Jiaxin Yuan, Xiaoxuan Xu, Zhiqi Zhang, Yize Li, Zixin Chen, Jinbing Xie, Zebin Xiao, Shenghong Ju   +14 more
wiley   +1 more source

BRCA mutations and childhood cancer [PDF]

Cancer Biology & Therapy, 2006
Commentary to:Childhood Cancer in Families with and without BRCA1 or BRCA2 Mutations Ascertained at a High-Risk Breast Cancer ClinicGabriel A. Brooks, Jill E. Stopfer, Julie Erlichman, Rebecca Davidson, Katherine L.
openaire   +2 more sources

Triple‐Negative Breast Cancer Cells Utilize IL8 and CXCL1 to Suppress NK Cells’ Function and Facilitate Cancer Metastasis

Advanced Science, EarlyView.
Triple‐negative breast cancer (TNBC) cells evade natural killer (NK) cell immunity by secreting IL8 and CXCL1. These chemokines suppress NK cells’ function via CXCR1/2 and enhance cancer cells’ survival through PD‐L1 upregulation and BCL‐2 anti‐apoptotic signaling.
Mingheng Yuan, Hongmei Yang, Renfei Wu, Meng Hao, Xiangpeng Chu, Chuxia Deng, Kathy Qian Luo   +6 more
wiley   +1 more source

Topology‐Aware Deep Learning on Higher‐Order Structures for Drug Response Prediction

Advanced Science, EarlyView.
We present TopDr, a topology‐aware deep learning framework that encodes both drugs and cell lines as multiscale simplicial complexes, capturing interactions at the 0‐, 1‐, and 2‐simplex levels. By jointly integrating local higher‐order neighborhoods and global topological structures, TopDr generates enriched representations for sensitivity prediction ...
Cong Shen, Guancen Lin, Chuan‐Shen Hu, Yong Wang   +3 more
wiley   +1 more source